Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: Transplant Cell Ther. 2021 Oct 2;27(12):993.e1–993.e8. doi: 10.1016/j.jtct.2021.08.031

Figure 1: Relapse and Non-relapse mortality.

Figure 1:

A: Relapse: The 1-year adjusted incidence of relapse was 31% (95% CI 27-35%) after planned G-CSF and 30% (95% CI 26-35%) without G-CSF, p=0·17

B: Non-relapse mortality: The 1-year adjusted incidence of non-relapse mortality was 21% (95% CI 18-25%) after planned G-CSF and 12% (95% CI 9-15%) without G-CSF, p<0·0001